Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes

Nicole C. Goodwin; Zhi‐Ming Ding; Bryce A. Harrison; Eric D. Strobel; Angela Harris; Melinda Smith; Andrea Y. Thompson; Wendy Xiong; Faika Mseeh; Debra Bruce; Damaris Diaz; Suma Gopinathan; Ling Li; Emily O’Neill; M. van Thiel; Alan Wilson; Kenneth G. Carson; David R. Powell; David B. Rawlins

doi:10.1021/acs.jmedchem.6b01541

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The increasing number of people afflicted with diabetes throughout the world is a major health issue. Inhibitors of the sodium-dependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patents. Herein we report the discovery of LX2761, a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Goodwin et al. (2017) studied this question.

synapsesocial.com/papers/6aa8f26d262dd5f9576bf956 https://doi.org/10.1021/acs.jmedchem.6b01541

View Full Paper

Ask AI

Bookmark

Share

Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes

Ask about this paper

Abstract

Discussion

Cite This Study

Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading